vimarsana.com
Home
Live Updates
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
/PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for...
Related Keywords
Germany ,
Shanghai ,
China ,
United States ,
Jinsheng ,
Shanxi ,
Hainan ,
United Kingdom ,
Canada ,
Nanjing ,
Jiangsu ,
Chinese ,
Ekevin Oliver ,
Zhou Gaobo ,
Andrew Zhu ,
Danny Chen ,
Bijoyesh Mookerjee ,
Simcere Pharmaceutical Group ,
Simcere Pharmaceutical ,
Shanghai Institute Of Materia Medica ,
Key Laboratory ,
Chinese Academy Of Sciences ,
Executive Vice President ,
Chief Medical Officer ,
Chief Investment Officer ,
Senior Vice President ,
Board Secretary ,
Shanghai Institute ,
Materia Medica ,
Chinese Academy ,
Treg Biased Fusion Proteins ,
Qianfoshan Hospital ,
Real Word Study ,
Chief Scientific Officer ,
State Key Laboratory ,
Pharmaceutical Group ,
Simcere Pharmaceutical Group Limited ,